This secondary analysis of
the Systolic Blood Pressure Intervention trial examines whether a treatment program aimed at reducing systolic blood pressure to a lower goal than currently recommended would reduce cardiovascular disease risk among patients without diabetes.
Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in
the Systolic Blood Pressure Intervention Trial.
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure:
the Systolic Blood Pressure Intervention Trial (SPRINT).
Earlier this year, preliminary results from the trial, named
the Systolic Blood Pressure Intervention Trial, or SPRINT, convinced the National Institutes of Health to end the study a year ahead of schedule (SN Online: 9/11/15).
Not exact matches
«What we're observing from the combined dietary
intervention is a reduction in
systolic blood pressure as high as, if not greater than, that achieved with prescription drugs,» says senior study author Lawrence Appel, M.D., M.P.H., professor of medicine at the Johns Hopkins University School of Medicine.
After 12 months, the average
systolic blood pressure decreased in both groups, but was lower in the
intervention group (128.2 / 73.8 mm Hg vs 137.8 / 76.3 mm Hg).
Behavioral counseling
interventions led to improvements in
systolic and diastolic
blood pressure levels, low - density lipoprotein cholesterol (LDL - C) levels, body mass index (BMI), and waist circumference that persisted over 6 to 12 months.
Husbands in the
intervention group had significantly lower post treatment 24 - hour
systolic blood pressure than the control group.
Net changes in
systolic and diastolic
blood pressure before and after the
intervention is the primary outcome.
Husbands in the
intervention group had significantly lower post treatment 24 - hour
systolic blood pressure than the control group.